⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 25, 2022Annals of Internal MedicineOpen Access

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

AstraZeneca.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Butt et al. (2022) studied this question.

synapsesocial.com/papers/69d98169c7f0c3ae80a3dc2a https://doi.org/10.7326/m21-4776

Topics

HFrEF treatment

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The Prevalence and Importance of Frailty in Heart Failure with Reduced Ejection Fraction – An Analysis of PARADIGM-HF and ATMOSPHEREOriginal Research · 2020 · 148 citations
2Frailty in Older Adults: Evidence for a PhenotypeCohort Study · 2001 · 24,716 citations
3The Frailty Syndrome and Outcomes in the TOPCAT Trialcohort · 2018 · 172 citations
4Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection FractionCohort Study · 2019 · 350 citations
5Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction2019 · 57 citations